Biomarkers in Invasive Pulmonary Fungal Infections: Where Do We Stand?

Area of Science:

• Medical Mycology
• Clinical Diagnostics
• Infectious Diseases

Background:

• Invasive pulmonary fungal infections cause significant morbidity and mortality in immunocompromised patients.
• Conventional diagnostic methods (culture, histopathology) have limitations in sensitivity and speed.
• Emerging biomarkers offer potential for earlier and more accurate detection.

Purpose of the Study:

• To review current evidence on optimal use of biomarkers for pulmonary fungal infections.
• To highlight challenges in interpreting diagnostic tests for specific pathogens and patient populations.
• To discuss the role of combined biomarkers in enhancing diagnostic accuracy.

Main Methods:

• Review of current evidence on galactomannan, β-D-glucan, and PCR assays.
• Analysis of biomarker performance based on pathogen, specimen type, and host population.
• Discussion of challenges and strategies for biomarker interpretation.

Main Results:

• Serological and molecular biomarkers show promise for early detection of aspergillosis and pneumocystosis.
• Diagnostic tools for mucormycosis are limited.
• PCR assays have potential but face implementation and standardization challenges.
• Antigen-based tests are anticipated to become available.

Conclusions:

• Optimal use of biomarkers requires understanding their strengths, limitations, and performance variations.
• Combining biomarkers can improve diagnostic accuracy and guide timely treatment decisions.
• Accurate interpretation is crucial given complex host factors, evolving fungal epidemiology, and expanding treatment options.